8-K: Century Therapeutics Secures $135M Private Placement

Century Therapeutics has secured an oversubscribed $135 million private placement to advance its lead Type 1 Diabetes program, CNTY-813, and extend its cash runway.

Summary

• Century Therapeutics, Inc. entered into a securities purchase agreement on January 7, 2026, for a private placement with institutional accredited investors.
• The company will issue 92,030,595 shares of common stock and/or 25,360,704 pre-funded warrants, along with warrants to purchase 58,695,648 shares of common stock or pre-funded warrants.
• The purchase price is $1.15 per share (or $1.1499 per pre-funded warrant) with an accompanying common warrant to purchase 0.5 shares.
• The pre-funded warrants are exercisable immediately at $0.0001 per share and do not expire.
• The common warrants are exercisable immediately at $2.60 per share (or $2.599 per pre-funded warrant) and expire on the earlier of 30 days after public announcement of initial Phase 1 clinical data for CNTY-813 or the third anniversary of the closing.
• The private placement is expected to close on or about January 9, 2026, and is anticipated to generate approximately $135.0 million in gross proceeds.
• Net proceeds will fund the development of the lead product candidate, CNTY-813, and for working capital and other general corporate purposes.
• Full exercise of the warrants could provide an additional approximately $153 million in gross proceeds.
• The company has agreed to file a registration statement covering the resale of the issued shares and underlying warrant shares no later than 30 days after closing.
• Placement agents for the transaction include Leerink Partners LLC, TD Securities (USA) LLC, and Mizuho Securities USA LLC.

Sentiment

Score: 8

Explanation: The filing indicates a strong positive sentiment due to a successful, oversubscribed capital raise that significantly extends the company's cash runway and funds critical clinical development programs. The investor confidence and progress in preclinical and early clinical studies are highly favorable, despite the inherent risks of biotech development and shareholder dilution.

Positives

• The oversubscribed private placement raised approximately $135 million, demonstrating strong investor confidence in the company's pipeline and strategy.
• The financing extends the company's cash runway to Q1 2029, providing capital beyond anticipated key clinical milestones.
• The funding is specifically allocated to advance CNTY-813, a potentially curative beta islet cell program for Type 1 Diabetes, which addresses a significant unmet medical need.
• Participation from leading investors like TCGX, RA Capital Management, and the T1D Fund validates the company's scientific approach and potential.
• Preclinical data for CNTY-813 shows promising results in restoring normoglycemia in STZ-rendered T1D mice and no observed outgrowths at 16 weeks post-transplant.
• The company's Allo-Evasion 5.0 technology is designed to protect cells from immune rejection, a critical factor for allogeneic cell therapies.
• The company has established in-house cGMP manufacturing capabilities, which can lead to quality product at disruptive scale and cost of goods.

Negatives

• The issuance of new shares and warrants will result in dilution for existing shareholders.
• The common warrants have an exercise price of $2.60, which is significantly higher than the $1.15 purchase price for the shares/pre-funded warrants, indicating a potential future dilution at a higher valuation but also a current discount for investors.
• The company is subject to liquidated damages if it fails to timely file or maintain the effectiveness of the resale registration statement, which could incur additional costs.

Risks

• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials.
• Uncertainties inherent in the results of preliminary data, pre-clinical studies, and earlier-stage clinical trials, which may not be predictive of final results or results of later-stage clinical trials.
• Ability to obtain clearance of future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all.
• Reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of product candidates.
• The timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval of product candidates.
• Impact of geopolitical issues, trade disputes and tariffs, banking instability, and inflation on business and operations, supply chain, and labor force.
• Performance of third parties in connection with the development of product candidates, including those conducting clinical trials and third-party suppliers and manufacturers.
• Ability to successfully commercialize product candidates and develop sales and marketing capabilities, if product candidates are approved.
• Ability to recruit and maintain key members of management and to maintain and successfully enforce adequate intellectual property protection.
• The company may be liable for liquidated damages if the registration statement for resale of the securities is not filed or declared effective within specified timelines, or if sales cannot be made under it.

Future Outlook

The company anticipates submitting an Investigational New Drug (IND) application for its lead product candidate, CNTY-813, in 2026, with initial clinical data expected in 2027. The CNTY-308 T cell program is expected to enter the clinic in 2026, and preliminary clinical data from the CNTY-101 Phase 1/2 CARAMEL IST is expected in 2026. This financing is projected to extend the company's cash runway to the first quarter of 2029, supporting these key clinical milestones.

Management Comments

• "We believe this financing further enables our ambition to unlock the full potential of our lead product candidate, CNTY-813, a potentially curative beta islet cell program for Type 1 diabetes."
• "We estimate this financing extends our cash runway to Q1 2029 with an anticipated IND submission for CNTY-813 in 2026 and initial clinical data for CNTY-813 expected in 2027."
• "We are grateful for the high level of conviction and confidence shown by top investors focused on supporting development of our potential therapies for high-impact diseases, beginning with Type 1 diabetes."

Industry Context

This financing positions Century Therapeutics to advance its iPSC-derived cell therapies, particularly in the competitive and high-potential fields of autoimmune diseases and Type 1 Diabetes. The focus on allogeneic, off-the-shelf therapies with immune evasion engineering (Allo-Evasion) aims to overcome limitations of autologous treatments, such as manufacturing complexity and patient access. The significant capital raise, led by specialized biotech investors, signals strong belief in the company's platform and lead programs, aligning with a broader industry trend towards innovative cell therapy approaches for chronic and complex diseases.

Comparison to Industry Standards

• CNTY-813 (iPSC Beta Islets with Allo-Evasion 5.0) is uniquely positioned to potentially deliver a successful T1D cell replacement therapy by offering glucose control, freedom from immune suppression, and a scalable drug product, unlike cadaveric islets (which require immune suppression and are not scalable) or other stem-cell beta islets (which typically require immune suppression).
• In preclinical studies, Century's iPSC-derived CAR-T cells (CNTY-308) are comparable to primary CAR-T cells in terms of IL-2 secretion, repeat killing capacity (>10 rounds), persistence in blood (32+ days), and tumor control after rechallenge, suggesting a competitive profile.
• Preliminary data from the CNTY-101 CARAMEL basket trial in autoimmune diseases shows deep B cell depletion and early efficacy, supporting the mechanism of action observed with autologous CAR T cell therapies in similar indications, such as those reported by Muller (2024) and Nordmann-Gomes (2025).

Corporate Governance

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience dilution from the issuance of new shares and warrants. However, the capital raise strengthens the company's financial position, potentially increasing the long-term value of their investment by funding critical development programs.
• **Investors (new)**: New institutional accredited investors are acquiring common stock and warrants at a specified price, gaining exposure to the company's pipeline with potential for future upside upon successful clinical development and warrant exercise.
• **Employees**: The extended cash runway provides greater job security and stability, allowing the company to continue its research and development efforts without immediate financial pressure.
• **Customers (future patients)**: The financing directly supports the development of potentially curative therapies for Type 1 Diabetes and autoimmune diseases, offering hope for future treatment options.
• **Creditors**: A stronger cash position and extended runway reduce financial risk, making the company a more stable entity for creditors.

Next Steps

• Closing of the private placement on or about January 9, 2026.
• Filing of a registration statement with the SEC covering the resale of the shares and warrant shares no later than 30 days following the closing of the private placement.
• IND submission for CNTY-813 planned for 2026.
• CNTY-308 iT cell program expected to enter the clinic in 2026.
• Preliminary clinical data from CNTY-101 Phase 1/2 CARAMEL IST expected in 2026.
• Initial clinical data for CNTY-813 expected in 2027.

Key Dates

Recommendation

The successful, oversubscribed $135 million private placement significantly de-risks Century Therapeutics' financial position, extending its cash runway to Q1 2029. This capital infusion is crucial for advancing its lead Type 1 Diabetes program, CNTY-813, and other promising iPSC-derived cell therapies (CNTY-308, CNTY-101) through key clinical milestones. The participation of prominent biotech investors signals strong confidence in the company's innovative Allo-Evasion technology and pipeline. While dilution is a factor, the enhanced financial stability and clear path to clinical data for high-impact programs outweigh this, presenting a compelling long-term growth opportunity for investors willing to accept the inherent risks of clinical-stage biotechnology.

Keywords

Century Therapeutics, IPSC, Private Placement, Capital Raise, Biotechnology, Cell Therapy, Type 1 Diabetes, CNTY-813, Allo-Evasion, Induced Pluripotent Stem Cell, CAR-T, CAR-NK, Autoimmune Disease, Clinical Trials, Warrants, Common Stock, Pre-Funded Warrants, SEC Filing, NASDAQ